Literature DB >> 21208295

Systemic influence of immunosuppressive drugs on small and large bowel transport and barrier function.

Maciej Malinowski1, Peter Martus, Johan Friso Lock, Peter Neuhaus, Martin Stockmann.   

Abstract

Immunosuppressive drug (ISD)-associated gastrointestinal disorders are a relevant risk factor for graft loss or patient death. The pathomechanisms and the incidence of post-transplantation diarrhea remain to be fully understood. The aim of this study was to characterize the impact of cyclosporine A, tacrolimus (TAC), mycophenolate mofetil (MMF), enteric coated mycophenolic acid (EC-MPA), sirolimus, everolimus (EVE) and fingolimod (FTY 720) on small and large bowel transport and barrier function. Functions of the small bowel and distal colon of Wistar rats treated for 14 days with one of the drug were analyzed using Ussing chamber method. In detail, the glucose and sodium absorption, chloride secretion, and barrier function were compared. Bowel functions were investigated by inhibition or activation of the electrogenic epithelial transport, as well as by measuring transepithelial H(3) -lactulose flux. TAC altered glucose absorption; EVE glucose absorption, small bowel barrier function and chloride secretion; MMF small bowel barrier function; and EC-MPA glucose absorption and the small bowel barrier function. Drug effects were partially dose-dependent. In conclusion, different ISD, such as TAC, EVE, MMF, or EC-MPA lead to different and specific patterns of pathophysiologic changes of small and large bowel barrier and transport function.
© 2011 The Authors. Transplant International © 2011 European Society for Organ Transplantation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21208295     DOI: 10.1111/j.1432-2277.2010.01167.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  6 in total

Review 1.  Adverse effects of immunosuppressant drugs upon airway epithelial cell and mucociliary clearance: implications for lung transplant recipients.

Authors:  Rogerio Pazetti; Paulo Manuel Pêgo-Fernandes; Fabio Biscegli Jatene
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

2.  Inhibition of mTOR protects the blood-brain barrier in models of Alzheimer's disease and vascular cognitive impairment.

Authors:  Candice E Van Skike; Jordan B Jahrling; Angela B Olson; Naomi L Sayre; Stacy A Hussong; Zoltan Ungvari; James D Lechleiter; Veronica Galvan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-12-22       Impact factor: 4.733

3.  MPA Modulates Tight Junctions' Permeability via Midkine/PI3K Pathway in Caco-2 Cells: A Possible Mechanism of Leak-Flux Diarrhea in Organ Transplanted Patients.

Authors:  Niamat Khan; Lutz Binder; D V Krishna Pantakani; Abdul R Asif
Journal:  Front Physiol       Date:  2017-06-26       Impact factor: 4.566

4.  End-Stage Renal Disease-Associated Gut Bacterial Translocation: Evolution and Impact on Chronic Inflammation and Acute Rejection After Renal Transplantation.

Authors:  Clémence Carron; Jean-Paul Pais de Barros; Emilie Gaiffe; Valérie Deckert; Hanane Adda-Rezig; Caroline Roubiou; Caroline Laheurte; David Masson; Dominique Simula-Faivre; Pascale Louvat; Bruno Moulin; Luc Frimat; Philippe Rieu; Christiane Mousson; Antoine Durrbach; Anne-Elisabeth Heng; Philippe Saas; Didier Ducloux; Laurent Lagrost; Jamal Bamoulid
Journal:  Front Immunol       Date:  2019-08-16       Impact factor: 7.561

5.  Immunosuppressant MPA Modulates Tight Junction through Epigenetic Activation of MLCK/MLC-2 Pathway via p38MAPK.

Authors:  Niamat Khan; D V Krishna Pantakani; Lutz Binder; Muhammad Qasim; Abdul R Asif
Journal:  Front Physiol       Date:  2015-12-22       Impact factor: 4.566

6.  Tacrolimus Induces Insulin Resistance and Increases the Glucose Absorption in the Jejunum: A Potential Mechanism of the Diabetogenic Effects.

Authors:  Zhiwei Li; Fei Sun; Yaohui Zhang; Hao Chen; Ningning He; Hui Chen; Penghong Song; Yan Wang; Sheng Yan; Shusen Zheng
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.